Lydia Torne

Lydia’s experience includes advising:

• GlaxoSmithKline on:
  • Its US$2 billion collaboration with ABL Biotechnology for the use of ABL’s proprietary best-in-class shuttle antibody technology, which facilitates penetration of the blood-brain barrier*
  • A multi-million dollar collaboration with Muna Therapeutics, leveraging Muna’s MiND-MAP platform to identify, validate, develop, and commercialize novel drug targets for Alzheimer’s disease*
  • A multi-million dollar collaboration with Relation Therapeutics, leveraging Relation’s Lab-in-the-Loop platform to identify, validate, develop, and commercialize novel drug targets for the treatment of osteoarthritis*
  • Its license with Adrestia Therapeutics for the use of platform software technology for the accelerated development of new drug products, as well as a related investment into, and sale of, Adrestia*
  • Its joint venture fund with Johnson & Johnson Innovation and AstraZeneca, Imperial Innovations, UCL Business, and Cambridge Enterprise to establish Apollo Therapeutics LLP to fund early-stage scientific research from Imperial College of Science, Technology and Medicine; University College London; and/or the University of Cambridge, for licensing to industry partners for further development and commercialization*
• Genmab on various strategic licensing agreements, including:
  • Its US$1.8 billion acquisition of Profound Bio, with its Rina-S molecule*
  • Its US$3.9 billion global license and collaboration agreement with AbbVie for the development and commercialization of three assets, including epcoritamab*
  • A leading collaboration with BioNTech for the development of novel cancer drugs*
• UCB on key foundational in-licenses with research institutes around the globe for early-stage development*
• Eisai on:
  • The exclusive worldwide license of its product E6005 (a selective PDE4 inhibitor) to Roivant Sciences*
  • Selling the European and UK rights to Targretin, a hematology specialty product with bexarotene as an active ingredient, to HAC Pharma*
• Cooper Consumer Healthcare on the IP, licensing, and regulatory aspects of its multi-billion dollar acquisition of Viatris’ OTC business*
• An international cosmetics company on acquiring a probiotics-based consumer health and cosmetics business*
• Institute of Global Health Innovation (IGHI) in connection with its strategic advice to the NHS regarding industry collaborations*
• Venture Life Group on various consumer health acquisitions and related licensing arrangements*
• Adherium on the long-term supply and development agreement for its smart inhaler with AstraZeneca*

*Matter handled prior to joining Latham